Skip to content

Checked

Class IIMedical device recallOngoing

TufTex¿ Over-the-Wire Embolectomy Catheter recall

Recalled by LeMaitre Vascular, Inc. of Burlington, MA · FDA report 10/14/2026

Not an official recall notice and may be delayed. Confirm with the manufacturer or the agency.

Class
Class II
Moderate
Status
Ongoing
Recall started
08/28/2026
Distribution
Nationwide

Reason for recall

Devices failed in process testing related to the amount of pull force it can sustain prior to the balloon components failing.

Class II: Use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.

Recalled product

Product
TufTex¿ Over-the-Wire Embolectomy Catheter; Catalog Number: E1651-88;
Lot and code info
Catalog Number: E1651-88; UDI-DI: 00840663100866; Lot Number: XOT00002181;
Quantity
54
Recall number
Z-0117-2027
Event ID
99836
Initiated by
Voluntary: Firm initiated

Where it was distributed

US Nationwide distribution in the states of CA, FL, GA, KY, LA, NJ, OH, PA, SC.

Recall timeline

  1. 08/28/2026Firm started the recall
  2. 10/07/2026FDA classified it as Class II
  3. 10/14/2026Published in the FDA enforcement report

More recalls from LeMaitre Vascular

Frequently asked questions

Why was TufTex¿ Over-the-Wire Embolectomy Catheter recalled?
Devices failed in process testing related to the amount of pull force it can sustain prior to the balloon components failing.
What does Class II mean?
Class II is FDA's moderate recall category: use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.
Where was the recalled product sold?
US Nationwide distribution in the states of CA, FL, GA, KY, LA, NJ, OH, PA, SC.
Is this recall still active?
The FDA lists the recall as ongoing. The recall is still in progress.

SEC company page: Lemaitre Vascular Inc (LMAT) · financials and records from other agencies

Source: U.S. Food and Drug Administration, openFDA enforcement report · Last updated 10/14/2026 · Do not rely on openFDA to make decisions regarding medical care